직장암의 항암화학요법 = Review : Chemotherapy in Rectal Cancer

참고문헌 (Reference)

1 "한국중앙암등록사업 2002 보고서"

2 "evidence in terms of response rate.Advanced Colorectal Cancer Meta-Analysis Project" 10 : 896-903, 1992

3 "The natural history of primary and secondary malignant tumors of the liver:the prognosis for patients with hepatic metastases from colonic and rectal carcinoma diagnosed by laparotomy" 23 : 198-202, 1969

4 "Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment" 22 : 1209-1214, 2004

5 "Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin" 21 : 2059-2069, 2003

6 "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer" 21 : 2787-2799, 2003

7 "Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/ LV5FU (Folfirinox)" 22 : 3613-, 2004

8 "Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity" 10 : 5151-5159, 2004

9 "Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer" 352 : 1407-1412, 1998

10 "Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer" 352 : 1413-1418, 1998

11 "Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer" 23 : 3508-, 2005

12 "Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer" 20 : 3617-3627, 2002

13 "Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients" 36 : 748-753, 2000

14 "Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer" 18 : 136-147, 2000

15 "Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer" 21 : 60-65, 2003

16 "Patterns of pelvic recurrence following definitive resections of rectal cancer" 53 : 1354-1362, 1984

17 "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer" 350 : 2343-2351, 2004

18 "Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer" 19 : 4097-4106, 2001

19 "OPTIMOX study" 22 : 3525-, 2004

20 "New oral anticancer drug, TS-1 (S-1)--from bench to clinic" 28 : 855-864, 2001

21 "Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer" 20 : 3605-3616, 2002

22 "Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer" 22 : 3766-3775, 2004

23 "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer" 18 : 2938-2947, 2000

24 "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer" 343 : 905-914, 2000

25 "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer" 355 : 1041-1047, 2000

26 "Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor" 108 : 2369-2379, 1995

27 "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders" 57 : 4593-4599, 1997

28 "High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer" 23 : 2-, 2005

29 "Final results of a phase III trial of 5-FU/leucovorin v oxaliplatin v the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin" 21 : 1011-, 2003

30 "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer" 22 : 229-237, 2004

31 "Estimates of cancer incidence and mortality in Europe in 1995" 38 : 99-166, 2002

32 "Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts" 8 : 994-1003, 2002

33 "Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer" 16 : 301-308, 1998

34 "EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer" 88 : 648-653, 2003

35 "EGFR expression and survival in stage II, III and IV colon cancer" 21 : 1272-, 2003

36 "Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer" 19 : 2282-2292, 2001

37 "Cetuximab-FOLFIRI as first-line treatment for metastatic colorectal CA" 22 : 3513-, 2004

38 "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer" 351 : 337-345, 2004

39 "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" 350 : 2335-2342, 2004

40 "Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure" 13 : 1558-1567, 2002

41 "An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX- 4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR)" 22 : 3512-, 2004

42 "A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer" 22 : 23-30, 2004

43 "A phase III trial comparing FULV to FULV+oxaliplatin in stage II or III carcinoma of the colon" 23 : 3500-, 2005